Journal article

A beta imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study

Kevin T Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Narelle Langdon, Ana M Catafau, Andrew W Stephens, John Seibyl, Ludger M Dinkelborg, Cornelia B Reininger, Barbara Putz, Beate Rohde, Colin L Masters, Christopher C Rowe

Journal of Neurology Neurosurgery & Psychiatry | BMJ PUBLISHING GROUP | Published : 2015


BACKGROUND: We assessed the clinical utility of β-amyloid (Aβ) imaging with (18)F-florbetaben (FBB) in mild cognitive impairment (MCI) by evaluating its prognostic accuracy for progression to Alzheimer's disease (AD), comparing semiquantitative with visual scan assessment, and exploring the relationships among Aβ, hippocampal volume (HV) and memory over time. METHODS: 45 MCI underwent FBB positron emission tomography, MRI and neuropsychological assessment at baseline and 2 years and clinical follow-up at 4 years. Positive FBB (FBB+), defined by a cortical to cerebellar cortex standardised uptake value ratio (SUVR) ≥ 1.45, was compared with visual assessment by five readers. Amnestic MCI (aMC..

View full abstract